

For personal use only



Half Year Report - Dec 2025



1. Company details

Name of entity:	Cryosite Limited
ABN:	86 090 919 476
Reporting period:	For the half-year ended 31 December 2025
Previous period:	For the half-year ended 31 December 2024
Reporting Currency:	Australian Dollars

2. Results for announcement to the market

	31 Dec 2025 \$'000	31 Dec 2024 \$'000	Change \$'000	Change %
Revenue from ordinary activities	8,273	6,640	1,633	25%
Profit before tax from ordinary activities	1,540	1,118	422	38%
Profit after tax from ordinary activities attributable to members	1,138	838	300	36%

Commentary on the results to the market

Results for half-year ending 31 December 2025 reflect a strengthening of trading conditions.

- Revenue of \$8,273,000, up 25%.
- Gross profit of \$5,088,000, up 20%.
- Earnings before interest, tax, depreciation and amortisation (EBITDA) of \$2,012,000, up 33%.
- Earnings before interest and tax (EBIT) of \$1,578,000, up 43%.
- Net Profit of \$1,138,000, up 36%. The Group recognised income tax expense of \$402,000 in 1HFY26, an increase of \$122,000 (44%) on the prior period

Dividends

In line with our growth strategy, the Board resolved not to declare a dividend for 1HFY26. The Group successfully completed an acquisition of a second warehouse facility at Auburn NSW in November 2025, which doubled our storage capacity to accommodate future growth.

A further explanation of the result of the current period is set out in the Directors' Report contained in the attached auditor reviewed Interim Report.

The Directors consider Earnings Before Interest and Tax ('EBIT') and Earnings Before Interest, Tax, Depreciation and Amortisation ('EBITDA') to reflect the core earnings of the Group. EBIT and EBITDA are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the profit under AAS adjusted for non-cash and significant items. The Group's reconciliation of its statutory net profit after tax ('NPAT') for the current and previous half-year to EBIT and EBITDA is as follows:

	Consolidated	
	31 Dec 2025 \$'000	31 Dec 2024 \$'000
Profit after tax	1,138	838
Add: Income tax expenses	402	280
Add: Interest	103	77
Less: Interest revenue calculated using effective interest method	(65)	(88)
EBIT	1,578	1,107
Add: Depreciation and amortisation	434	411
EBITDA	2,012	1,518

3. Net tangible assets backing

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>8.01</u>	<u>3.15</u>

The calculation of net tangible assets excludes right-of-use assets, intangible assets, and lease liabilities.

4. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

	Amount per security Cents	Franked amount per security Cents
Final unfranked dividend paid during the half-year ended 31 December 2024	2.00	-

5. Audit qualification or review

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

6. Attachments

The Interim Report of Cryosite Limited for the half-year ended 31 December 2025 is attached.

7. Signed

Signed  _____

Date: 26 February 2026

Mark Kerr
Non-Executive Chairman

For personal use only

Cryosite Limited

ABN 86 090 919 476

Interim Report - 31 December 2025

For personal use only

Directors' report	2
Auditor's independence declaration	8
Consolidated statement of profit or loss and other comprehensive income	9
Consolidated statement of financial position	10
Consolidated statement of changes in equity	11
Consolidated statement of cash flows	12
Notes to the consolidated financial statements	13
Directors' declaration	28
Independent auditor's report to the members of Cryosite Limited	29

For personal use only

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Cryosite Limited (referred to hereafter as 'Cryosite', the 'Company' or 'parent entity') and the entity it controlled at the end of, or during, the half-year ended 31 December 2025.

Directors

The following persons were directors of Cryosite Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Mark Kerr	Non-Executive Chairman
Andrew Kerr	Executive Director
Scott Thomas	Non-Executive Director

Principal activities

Cryosite provides specialised, temperature-controlled logistics and depot services, including secure storage, labelling, secondary packaging, import/export coordination, inventory management, distribution, destruction, and reverse logistics.

The Group supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Advanced Therapy Medicinal Products (ATMPs), Research and Development (R&D) materials, and medical devices.

Services are structured around the following temperature-controlled storage and distribution capabilities:

- (1) **Ambient (15°C to 25°C), cold (2°C to 8°C), and frozen (-20°C):** Storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions. This includes Good Manufacturing Practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements.
- (2) **Ultra-frozen (-80°C) and cryogenic (<-150°C):** Specialised handling of materials requiring Ultra-Frozen or Cryogenic conditions, including Advanced Therapy Medicinal Products (ATMPs), such as Cell and Gene Therapies (CGT), cell therapies, mRNA-based medicines (inc. vaccines), biological samples, and Research and Development (R&D) materials requiring high-integrity cold storage (e.g. plasma, tissue, reagents).
- (3) **Cord blood (<-150°C):** Storage of cord blood cell and tissue samples for personal or directed therapeutic use, maintained under validated chain-of-identity controls.

Review of operations

The half-year ended 31 December 2025 represented a period of step-change performance for Cryosite. The Group delivered record revenue, earnings and operating volumes, reflecting the collective impact of sustained investment in specialist people, infrastructure and systems.

Our growth was broad-based across clinical trials, biologics, ARTG medicines and advanced therapies, with accelerating demand seen across all temperature-controlled segments. Importantly, this growth was achieved while maintaining industry-leading quality outcomes and service reliability.

Operational momentum during the period highlights Cryosite's transition from a phase of capability build-out to one of scalable, capacity-led growth.

Cryosite's 1HFY26 performance reflects the continued strength of our operations and the benefits of considered capital investment over the past several years:

	1HFY26 (\$'000)	% Change	1HFY25 (\$'000)
Revenue	8,273	25%	6,640
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA)	2,012	33%	1,518
<i>EBITDA Margin</i>	24%	1%	23%
Earnings Before Interest and Tax (EBIT)	1,578	43%	1,107
Net Profit After Tax (NPAT)	1,138	36%	838
<i>NPAT Margin</i>	14%	1%	13%

- **Operational volumes:** increased 30% year-on-year
- **Quality performance:** Cryosite's team continued to achieve industry-leading quality metrics
- The Group ended 1HFY26 with a **strong cash balance of \$2,538,000** (30 June 2025: \$5,060,000), driven by robust operational cashflows, which were offset by a \$3,452,000 equity and transaction cost contribution relating to the acquisition of our new freehold facility at 100-104 Adderley St West, Auburn, NSW.

On an unaudited basis, January 2026 reflected strong operating cashflows. Cryosite had Cash on hand at 31 January 2026: \$3,139,000 (31 January 2025 \$4,574,000), and Net Cash Flows from Operating Activities of \$1,926,000, an increase of 50% vs. 31 January 2025 (\$1,287,000).

During the period, Cryosite initiated two significant growth initiatives, providing critical capacity expansion to meet accelerating demand:

- (1) **Acquisition of new freehold facility (Adderley St):** During the period, Cryosite completed the acquisition of a new freehold facility at 100–104 Adderley St West, Auburn, NSW, representing a significant milestone in the Group's long-term growth strategy. Conveniently located approx. 15 minutes' drive from our existing facility at Ferndell St, South Granville, the acquisition more than doubles the Group's usable storage and warehousing footprint (to 4,200+ sqm) and provides critical capacity relief as demand across regulated temperature-controlled services continues to accelerate.

The acquisition was funded through a combination of operating cashflows and a competitively priced debt facility from the National Australia Bank (NAB) secured at approximately 70% loan-to-value, with interest-only terms. This structure preserves balance sheet flexibility while providing long-term control over strategically important infrastructure.

The NAB facility has a contractual maturity of 30 October 2026 and is interest-only until maturity. As this date falls within 12 months of the reporting date, the facility is classified as a current liability in accordance with accounting standards. This presentation reflects contractual timing only. The Directors are in active discussions with the NAB regarding extension or refinancing of the facility and are confident of securing long-term funding arrangements prior to maturity.

Adderley St Acquisition	\$'000
Cash (Equity and transaction costs)	3,452
Debt	6,650
Total acquisition costs	<u>10,102</u>

- (2) **Expansion of large-scale cool room (Ferndell St):** In December 2025, construction works commenced to extend the primary large-scale cool room (2°C to 8°C) at our Ferndell St facility. This expansion was enabled by the additional operational flexibility provided through the Adderley St acquisition. The cool room expansion will nearly double our capacity of 2°C to 8°C storage, which has seen utilisation increase approx. 40% in the last 12 months.

These expansion projects are progressing on time and on budget and are funded from operating cashflows.

Earnings per share

Cents
31 Dec 2025 31 Dec 2024

Basic earnings per share	2.33	1.72
Diluted earnings per share	2.24	1.72

Overview

The Directors are pleased to report the financial results for the half-year ended 31 December 2025 have materially exceeded those of the prior corresponding period. Strong growth was delivered across revenue, operating profit, EBIT and EBITDA, demonstrating continued execution against Cryosite's long-term strategy and disciplined capital deployment.

The Group continues to benefit from defensible positions in regulated supply chains, long-duration customer relationships and increasing global demand for specialist temperature-controlled storage and logistics.

The Directors consider Earnings Before Interest and Tax ('EBIT') and Earnings Before Interest, Tax, Depreciation and Amortisation ('EBITDA') to reflect the core earnings of the Group. EBIT and EBITDA are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the profit under AAS adjusted for non-cash and significant items. The Group's reconciliation of its statutory net profit after tax ('NPAT') for the current and previous half-year to EBIT and EBITDA is as follows:

	31 Dec 2025 \$'000	31 Dec 2024 \$'000	Change \$'000	Change %
Reported financials				
Revenue	8,273	6,640	1,633	25%
Cost of providing services	(3,185)	(2,389)	(796)	33%
Gross profit	5,088	4,251	837	20%
Net profit after tax	1,138	838	300	36%
Add: Income tax expense	402	280	122	44%
Add: Interest expenses	103	77	26	34%
Less: Interest revenue calculated using effective interest method	(65)	(88)	23	(26%)
EBIT	1,578	1,107	471	43%
Add: Depreciation and amortisation expense	434	411	23	6%
EBITDA	2,012	1,518	494	33%

Ultra-Frozen and Cryogenic

The Ultra-Frozen and Cryogenic segment continued to develop as a key growth driver during 1HFY26. Demand increased from both existing and new clinical trial sponsors, reflecting global growth in cell and gene therapies and Cryosite's reputation for regulatory compliance and execution.

This segment benefits from high barriers to entry, long-term customer relationships and increasing regulatory complexity, supporting sustainable margins and client retention.

1HFY26 Ultra-Frozen and Cryogenic highlights:

- **Revenue** increased by 63% to \$1,218,000 (1HFY25: \$747,000)
- **EBITDA** increased by 44% to \$460,000 (1HFY25: \$320,000)
- **Active client/clinical trial sponsors** - increased by 39% on 1HFY25

The results for 1HFY26 reflect a business operating on an accelerating scale, with the foundations in place to support further expansion as demand across regulated temperature-controlled services continues to grow.

I would like to thank our dedicated staff, loyal clients and committed shareholders for their ongoing support. Our growth and momentum are the result of trusted client relationships, disciplined execution by our team, and the continued backing of our shareholders.

Cashflow

The Group remains in a strong financial position with **Cash on hand at 31 December 2025: \$2,538,000** (a decrease of \$2,522,000 on 30 June 2025: \$5,060,000).

Cryosite generated strong operating cashflows during the half-year, reflecting improved profitability and disciplined working capital management, preserving a strong liquidity position to support future growth.

Movements in cash on hand during the period reflect capital expenditure associated with the acquisition of our freehold warehouse facility at 100-104 Adderley St West, Auburn, NSW, (\$3,452,000) and higher income tax payments following utilisation of historical tax losses.

Dividends

Dividends paid during the financial half-year were as follows:

	Consolidated	
	31 Dec	31 Dec
	2025	2024
	\$'000	\$'000

Final unfranked dividend paid during the half-year for the year ended 31 December 2025 of nil cents (31 December 2024: 2.0 cents) per ordinary share	-	976
--	---	-----

In line with Cryosite's growth strategy, no interim dividend was declared for 1HFY26. The Board remains focused on reinvesting in high-return expansion opportunities while maintaining balance sheet flexibility and optionality.

As at 31 December 2025, the Group had accumulated franking credits of \$580,000. These credits provide flexibility for the Board to consider future fully or partially franked dividends, enhancing the potential after-tax value of distributions to shareholders when appropriate.

Environmental, social and governance (ESG)

Cryosite remains committed to sustainable and responsible business practices. During the period, the Group executed on its strategy of continuous improvement in ESG initiatives ahead of an annual review in 2HFY26 by EcoVadis. Cryosite was awarded a Gold Medal by EcoVadis in 2025, recognising strong performance across environmental, labour and human rights, ethics and sustainable procurement.

Key ESG initiatives during the half-year included continued investment in energy-efficient infrastructure and GreenPower, the introduction of a paid parental leave policy and ongoing workforce development and safety programs.

Cryosite remains committed to reducing GHG emissions. Our objective is to understand, manage, and reduce our greenhouse gas emissions across all operational activities. Our Scope 1 and Scope 2 greenhouse gas emissions for 1HFY26 were approx. 221 tonnes of carbon dioxide equivalent (CO2e).

Stability in the state of affairs

Our stability in a changing industry landscape reflects effective strategic planning and execution. It highlights our ability to maintain a steady course while adapting to the evolving needs of our clients and the market.

Governance and Management

The Board upholds the highest standards of corporate governance and ethical behaviour. Enhancements in 1HFY26 included:

- Continued review of governance policies
- Strengthening supplier due diligence and sustainability reporting standards
- Enhancement of internal controls to ensure compliance with regulatory obligations and best-practice corporate governance as the Group scales

Material business risks

The Board actively monitors risks that could impact operations and financial performance. The Group's risk management framework includes robust internal controls, ongoing investment in operational resilience, and regular reviews of emerging threats.

Macroeconomic

Although the Group holds a strong market position, it is not immune to inflationary pressures, supply chain disruptions, and new market entrants.

The Group monitors economic indicators closely and maintains a diversified customer base, including growth in biological storage and cell & gene therapies storage leveraging over 24 years of cryogenic cord blood expertise.

Regulatory compliance

The Group's modern, purpose-built facility is licensed by the Therapeutic Goods Administration (TGA), certified to Good Manufacturing Practice (GMP) standards, and NSW Health for Good Wholesaling Practice of Scheduled medicines.

- Conducts regular audits to ensure compliance with regulatory and customer standards;
- Maintains comprehensive accreditations with management systems that underpin quality assurance; and
- Implements internal controls to ensure adherence to Australian laws and regulations.

Privacy and cybersecurity

Protecting sensitive data remains a top priority with:

- The Group investing in IT infrastructure and staff training; and
- Cybersecurity systems are being aligned with the Australian Signals Directorate (ASD) Essential Eight Maturity Model.

Work, health and safety ('WHS')

The Group has a zero-tolerance approach to serious incidents and promotes a strong safety culture through:

- Continuous improvement of WHS practices
- Ongoing employee training and engagement in safety programs

Operating risks

- As part of a global clinical trials supply chain, disruptions (such as those experienced during COVID-19) can present challenges and opportunities. Agile operating procedures are in place to respond effectively.
- The Clinical Trials division relies on global pharmaceutical and biotech companies. The Group mitigates concentration risk through client diversification and maintaining high service standards.
- The entry of new competitors or changes in clinical trial delivery models could impact operations. This is mitigated by maintaining licenses and certifications, investing in facilities and services, and strengthening customer relationships and brand reputation both domestically and internationally.

Significant changes in the state of affairs

The Group completed the acquisition of a freehold warehouse property at 100-104 Adderley St West, Auburn, NSW, for approximately \$9.5 million. The acquisition provides additional capacity (over 100%), long-term operational flexibility and greater control over infrastructure as Cryosite continues to scale.

There were no other significant changes in the state of affairs of the Group during the financial half-year.

Rounding of amounts

The Group is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in black ink that reads "Mark Kerr". The signature is enclosed in a thin black rectangular box.

Mark Kerr
Non-Executive Chairman

26 February 2026

For personal use only

Auditor's Independence Declaration to the Directors of Cryosite Limited

In relation to our review of the financial report of Cryosite Limited and its controlled entity for the half-year ended 31 December 2025 to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Cryosite Limited and its controlled entity during the half-year ended 31 December 2025.



Forvis Mazars Audit & Assurance Pty Ltd



Alexis Aupied

Director

26 February 2026

Cryosite Limited
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2025



		Consolidated	
	Note	31 Dec 2025 \$'000	31 Dec 2024 \$'000
Revenue	5	8,273	6,640
Expenses			
Administration expenses		(2,626)	(2,379)
Cost of providing services		(3,185)	(2,389)
Depreciation and amortisation expense	6	(434)	(411)
Marketing expenses		(34)	(24)
Occupancy expenses		(416)	(330)
Total expenses		<u>(6,695)</u>	<u>(5,533)</u>
Operating profit		1,578	1,107
Interest revenue calculated using the effective interest method		65	88
Finance costs	6	<u>(103)</u>	<u>(77)</u>
Profit before income tax expense		1,540	1,118
Income tax expense	7	<u>(402)</u>	<u>(280)</u>
Profit after income tax expense for the half-year attributable to the owners of Cryosite Limited		1,138	838
Other comprehensive income for the half-year, net of tax		<u>-</u>	<u>-</u>
Total comprehensive income for the half-year attributable to the owners of Cryosite Limited		<u><u>1,138</u></u>	<u><u>838</u></u>
		Cents	Cents
Basic earnings per share	8	2.33	1.72
Diluted earnings per share	8	2.24	1.72

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

For personal use only

		Consolidated	
	Note	31 Dec 2025 \$'000	30 Jun 2025 \$'000
Assets			
Current assets			
Cash and cash equivalents	9	2,538	5,060
Trade and other receivables	10	2,592	2,285
Inventories - stock on hand		72	43
Customer acquisition and fulfilment costs	11	998	1,038
Other assets		286	443
Total current assets		6,486	8,869
Non-current assets			
Property, plant and equipment	12	11,491	1,415
Right-of-use assets	13	1,869	1,999
Intangibles assets		-	-
Deferred tax assets		988	989
Customer acquisition and fulfilment costs	11	5,513	5,992
Other assets		198	200
Total non-current assets		20,059	10,595
Total assets		26,545	19,464
Liabilities			
Current liabilities			
Trade and other payables		1,678	1,731
Contract liabilities		2,043	2,021
Borrowings	14	6,650	-
Lease liabilities		209	199
Provision for income tax		260	165
Employee benefits		314	349
Other liabilities	15	67	67
Total current liabilities		11,221	4,532
Non-current liabilities			
Trade and other payables		442	442
Contract liabilities		8,763	9,501
Lease liabilities		1,959	2,068
Employee benefits		115	96
Provisions		209	209
Other liabilities	15	227	227
Total non-current liabilities		11,715	12,543
Total liabilities		22,936	17,075
Net assets		3,609	2,389
Equity			
Issued capital	16	3,538	3,538
Reserve		114	32
Accumulated losses		(43)	(1,181)
Total equity		3,609	2,389

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

Consolidated	Issued capital \$'000	Reserve \$'000	Accumulated losses \$'000	Total equity \$'000
Balance at 1 July 2024	3,538	-	(2,089)	1,449
Profit after income tax expense for the half-year	-	-	838	838
Other comprehensive income for the half-year, net of tax	-	-	-	-
Total comprehensive income for the half-year	-	-	838	838
<i>Transactions with owners in their capacity as owners:</i>				
Dividends paid (note 17)	-	-	(976)	(976)
Balance at 31 December 2024	3,538	-	(2,227)	1,311
Consolidated	Issued capital \$'000	Reserve \$'000	Accumulated losses \$'000	Total equity \$'000
Balance at 1 July 2025	3,538	32	(1,181)	2,389
Profit after income tax expense for the half-year	-	-	1,138	1,138
Other comprehensive income for the half-year, net of tax	-	-	-	-
Total comprehensive income for the half-year	-	-	1,138	1,138
<i>Transactions with owners in their capacity as owners:</i>				
Share-based payments	-	82	-	82
Balance at 31 December 2025	3,538	114	(43)	3,609

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

		Consolidated	
	Note	31 Dec 2025 \$'000	31 Dec 2024 \$'000
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		7,517	5,772
Payments to suppliers and employees (inclusive of GST)		(5,928)	(4,505)
Interest and other finance costs paid		(61)	(77)
Income taxes paid		(307)	(50)
		<u>1,221</u>	<u>1,140</u>
Cash flows from investing activities			
Payments for property, plant and equipment	12	(3,648)	(305)
Interest received		82	80
		<u>(3,566)</u>	<u>(225)</u>
Cash flows from financing activities			
Dividends paid	17	-	(976)
Repayment of lease liabilities		(176)	(155)
		<u>(176)</u>	<u>(1,131)</u>
Net cash used in financing activities		<u>(176)</u>	<u>(1,131)</u>
Net decrease in cash and cash equivalents		(2,521)	(216)
Cash and cash equivalents at the beginning of the financial half-year		5,060	4,703
Effects of exchange rate changes on cash and cash equivalents		(1)	-
		<u>(1)</u>	<u>-</u>
Cash and cash equivalents at the end of the financial half-year		<u><u>2,538</u></u>	<u><u>4,487</u></u>

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. General information

The financial statements cover Cryosite Limited as the Group consisting of Cryosite Limited and the entity it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Cryosite Limited's functional and presentation currency.

Cryosite Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

13a Ferndell Street
South Granville
NSW 2142

A description of the Group's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 26 February 2026.

Note 2. Material accounting policies

These general purpose financial statements for the interim half-year reporting period ended 31 December 2025 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by the Group during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Group during the half-year ended 31 December 2025 and are not expected to have a significant impact for the full financial year ending 30 June 2026.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 3. Going concern

The financial statements have been prepared on a going concern basis, which assumes that the Group will be able to realise its assets and discharge its liabilities in the normal course of business.

As disclosed in note 14, the Group has a secured NAB Corporate Markets Loan facility of \$6.65 million which is interest-only and contractually repayable in full on 30 October 2026. The facility is secured by a registered mortgage over the Group's freehold property located at 100–104 Adderley Street West, Auburn NSW, together with general security agreements.

For the half-year ended 31 December 2025, the Group generated net operating cash inflows of \$1.264 million and reported EBITDA of \$2.012 million. At 31 December 2025, the Group held cash and cash equivalents of \$2.538 million. Trading performance in the first half of FY26 reflects continued growth in revenue and profitability compared to the prior corresponding period.

While the NAB facility matures in October 2026, management has commenced discussions with its lender regarding refinancing of the facility. The Directors note that:

- The loan is secured against a freehold property recorded at \$10.102 million at 31 December 2025.
- The loan-to-value ratio remains within commercial banking parameters.
- The Group continues to generate positive operating cash flows.
- The facility is interest-only, with no principal repayments required prior to maturity.

Based on the Group's current financial position, forecast cash flows, and asset backing, the Directors are satisfied that the Group will be able to refinance and meet its obligations when they fall due. Accordingly, the Directors consider it appropriate to prepare the financial statements on a going concern basis.

Note 4. Operating segments

Identification of reportable operating segments

In 1H FY26, the Group experienced material growth in Ultra-Frozen and Cryogenic revenues. As a result, the Directors have elected to separate the former **Clinical Trails and Biological Services Logistics** segment into two new streams based on their controlled-temperature ranges: **Ambient, Cold, and Frozen, and Ultra-Frozen and Cryogenic**. There were no changes to the Cord Blood reporting segment.

These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

Ambient, cold, and frozen	Storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions. This includes Good Manufacturing Practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements.
Ultra-frozen and cryogenic	Specialised handling of materials requiring Ultra-Frozen or Cryogenic conditions, including Advanced Therapy Medicinal Products (ATMPs), such as Cell and Gene Therapies (CGT), cell therapies, mRNA-based medicines (inc. vaccines), biological samples, and Research and Development (R&D) materials requiring high-integrity cold storage (e.g. plasma, tissue, reagents).
Cord blood	Storage of cord blood cell and tissue samples for personal or directed therapeutic use, maintained under validated chain-of-identity controls.

The CODM review EBITDA (earnings before interest, tax, depreciation and amortisation). The accounting policies adopted for internal reporting to the CODM are consistent with those adopted in the financial statements.

The information reported to the CODM is on a monthly basis.

Note 4. Operating segments (continued)

Major customers

The Group services a highly specialised and often concentrated market segment, of which during the half-year ended 31 December 2025, approximately 73% (31 December 2024: 76%) of the Group's external revenue was derived from sales to three major global clients.

Operating segment information

Consolidated - 31 Dec 2025	Ambient cold, and frozen \$'000	Ultra-frozen and cryogenic \$'000	Cord blood \$'000	Corporate \$'000	Total \$'000
Revenue					
Sales to external customers	5,884	1,218	1,171	-	8,273
Interest revenue	-	-	-	-	-
Total revenue	<u>5,884</u>	<u>1,218</u>	<u>1,171</u>	<u>-</u>	<u>8,273</u>
EBITDA	2,332	460	385	(1,165)	2,012
Depreciation and amortisation expense	(219)	(85)	(10)	(120)	(434)
Interest revenue	-	-	-	65	65
Finance costs	(35)	(17)	(5)	(46)	(103)
Profit/(loss) before income tax expense	<u>2,078</u>	<u>358</u>	<u>370</u>	<u>(1,266)</u>	<u>1,540</u>
Income tax expense					(402)
Profit after income tax expense					<u>1,138</u>
Assets					
Segment assets	3,108	734	7,407	15,296	26,545
Total assets					<u>26,545</u>
Liabilities					
Segment liabilities	1,434	113	11,187	10,202	22,936
Total liabilities					<u>22,936</u>

Note 4. Operating segments (continued)

	Ambient cold, and frozen \$'000	Ultra-frozen and cryogenic \$'000	Cord blood \$'000	Corporate \$'000	Total \$'000
Consolidated - 31 Dec 2024					
Revenue					
Sales to external customers	4,730	747	1,163	-	6,640
Interest revenue	-	-	-	-	-
Total revenue	4,730	747	1,163	-	6,640
EBITDA					
Depreciation and amortisation expense	2,156	320	333	(1,291)	1,518
Depreciation and amortisation expense	(295)	(54)	(14)	(48)	(411)
Interest revenue	-	-	-	88	88
Finance costs	(44)	(11)	(6)	(16)	(77)
Profit/(loss) before income tax expense	1,817	255	313	(1,267)	1,118
Income tax expense					(280)
Profit after income tax expense					838
Consolidated - 30 Jun 2025					
Assets					
Segment assets	2,937	708	7,969	7,850	19,464
Total assets					19,464
Liabilities					
Segment liabilities	1,267	81	11,932	3,795	17,075
Total liabilities					17,075

Geographical information

The sales to external customers for both operating segments are from Australia.

Note 5. Revenue

	Consolidated	
	31 Dec 2025 \$'000	31 Dec 2024 \$'000
<i>Revenue from contracts with customers</i>		
Revenue from ambient, cold, and frozen	5,884	4,730
Revenue from ultra-frozen and cryogenic	1,218	747
Revenue from cord blood (i)	1,171	1,163
Revenue	8,273	6,640
Consolidated		
	31 Dec 2025 \$'000	31 Dec 2024 \$'000
<i>(i) Cord blood comprised of:</i>		
Cord blood revenue	356	268
Cord blood historical contract revenue	815	895
Total cord blood revenue	1,171	1,163

Note 5. Revenue (continued)

	31 Dec 2025 \$'000	Consolidated 31 Dec 2024 \$'000
* Cord blood deferred revenues and costs are comprised of:		
Cord blood historical contract liabilities	815	895
Cord blood historical contract assets	(519)	(563)
Cord blood historical deferred income tax expense	(74)	(83)
	<u>222</u>	<u>249</u>

* Refer to note 4 'Operating segments'.

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

	31 Dec 2025 \$'000	Consolidated 31 Dec 2024 \$'000
<i>Geographical regions</i>		
Australia*	<u>8,273</u>	<u>6,640</u>
<i>Timing of revenue recognition</i>		
Goods transferred at a point in time	7,102	3,488
Services transferred over time	1,171	3,152
	<u>8,273</u>	<u>6,640</u>

* The geographical regions are determined based on the place where the services occur.

Note 6. Expenses

	Consolidated	Consolidated
	31 Dec	31 Dec
	2025	2024
	\$'000	\$'000
Profit before income tax includes the following specific expenses:		
<i>Depreciation and amortisation expense</i>		
Depreciation - Property plant and equipment	222	279
Depreciation - Right-of-use assets	130	130
Amortisation - Intangibles assets	-	2
Amortisation - Employee options	82	-
Total depreciation and amortisation	<u>434</u>	<u>411</u>
<i>Finance costs</i>		
Interest portion of monies owed to ACCC	9	11
Interest and finance charges paid/payable on lease liabilities	61	66
Interest on the NAB loan	33	-
Finance costs expensed	<u>103</u>	<u>77</u>
<i>Superannuation expense</i>		
Defined contribution superannuation expense	191	177
<i>Employee benefits expense excluding superannuation</i>		
Employee benefits expense excluding superannuation	<u>1,558</u>	<u>1,346</u>

Note 7. Income tax

	Consolidated	Consolidated
	31 Dec	31 Dec
	2025	2024
	\$'000	\$'000
<i>Income tax expense</i>		
Current tax	406	270
Deferred tax - origination and reversal of temporary differences	(4)	10
Aggregate income tax expense	<u>402</u>	<u>280</u>
<i>Numerical reconciliation of income tax expense and tax at the statutory rate</i>		
Profit before income tax expense	<u>1,540</u>	<u>1,118</u>
Tax at the statutory tax rate of 25%	385	280
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Tax adjustment relating to consolidation	17	-
Income tax expense	<u>402</u>	<u>280</u>

The income tax expense is recognised based on the best estimate of the weighted average annual income tax rate. The estimate takes into account the unutilised tax losses and anticipated tax payable.

Note 8. Earnings per share

	Consolidated	
	31 Dec 2025 \$'000	31 Dec 2024 \$'000
Profit after income tax attributable to the owners of Cryosite Limited	<u>1,138</u>	<u>838</u>
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	48,809,563	48,809,563
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares	<u>2,000,000</u>	<u>-</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>50,809,563</u>	<u>48,809,563</u>
	Cents	Cents
Basic earnings per share	2.33	1.72
Diluted earnings per share	2.24	1.72

There have been no other transactions involving ordinary shares or potential ordinary shares since the reporting date and before completion of these financial statements.

For personal use only

Note 9. Cash and cash equivalents

	Consolidated	
	31 Dec	30 Jun
	2025	2025
	\$'000	\$'000
<i>Current assets</i>		
Cash at bank and on hand	1,038	1,060
Short-term deposits	1,500	4,000
	<u>2,538</u>	<u>5,060</u>

Cash at bank and on hand earns interest at floating rates based on daily bank deposit rates. Short-term deposit is made for varying periods of between one day and six months depending on the immediate cash requirements of the Group and earn interest at the respective short-term deposit rates.

Note 10. Trade and other receivables

	Consolidated	
	31 Dec	30 Jun
	2025	2025
	\$'000	\$'000
<i>Current assets</i>		
Trade receivables	2,531	2,148
Accrued receivables	154	171
Less: Allowance for expected credit losses	(150)	(93)
	<u>2,535</u>	<u>2,226</u>
Other receivables	57	59
	<u>2,592</u>	<u>2,285</u>

Note 11. Customer acquisition and fulfilment costs

	Consolidated	
	31 Dec	30 Jun
	2025	2025
	\$'000	\$'000
<i>Current assets</i>		
Deferred costs - cord blood	998	1,038
<i>Non-current assets</i>		
Deferred costs - cord blood	5,513	5,992
	<u>6,511</u>	<u>7,030</u>
<i>Reconciliation of historical deferred cost cord blood</i>		
Opening balance	7,030	8,156
Recognised in the current half-year/year	(519)	(1,126)
Closing balance	<u>6,511</u>	<u>7,030</u>

Deferred costs represent upfront costs, such as laboratory fees, attributable for the collection and processing of cord blood and tissue samples.

Note 12. Property, plant and equipment

	Consolidated	
	31 Dec 2025 \$'000	30 Jun 2025 \$'000
<i>Non-current assets</i>		
Land and buildings - at cost	10,102	-
Leasehold improvements - at cost	149	149
Less: Accumulated depreciation	(136)	(125)
	<u>13</u>	<u>24</u>
Fixtures and fittings - at cost	156	156
Less: Accumulated depreciation	(135)	(131)
	<u>21</u>	<u>25</u>
Information technology - at cost	346	276
Less: Accumulated depreciation	(261)	(244)
	<u>85</u>	<u>32</u>
Office furniture and equipment - at cost	70	68
Less: Accumulated depreciation	(51)	(45)
	<u>19</u>	<u>23</u>
Warehouse equipment - at cost	4,926	4,911
Less: Accumulated depreciation	(3,785)	(3,600)
	<u>1,141</u>	<u>1,311</u>
Tangible assets under construction - at cost	110	-
	<u>11,491</u>	<u>1,415</u>

Reconciliations

Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:

	Land and buildings	Leasehold improve- ments	Fixtures and fittings	Information technology	Office furniture and equipment	Warehouse equipment	Tangible assets under construction	Total
Consolidated	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Balance at 1 July 2025	-	24	25	32	23	1,311	-	1,415
Additions	10,102	-	-	70	2	14	110	10,298
Depreciation expense	-	(11)	(4)	(17)	(6)	(184)	-	(222)
Balance at 31 December 2025	<u>10,102</u>	<u>13</u>	<u>21</u>	<u>85</u>	<u>19</u>	<u>1,141</u>	<u>110</u>	<u>11,491</u>

During the reporting period, the Group completed the acquisition of a new warehouse property at 100–104 Adderley Street West, Auburn, NSW for a total consideration of **\$10.1 million**, inclusive of land, building and directly attributable acquisition costs.

Note 12. Property, plant and equipment (continued)

The acquisition was funded through a combination of:

- \$3.45 million from existing cash reserves; and
- A new \$6.65 million secured interest-only bank loan facility. Ref to note 14.

The warehouse will be used to support the Group's operational activities and is classified within property, plant and equipment. The asset was initially recognised at cost in accordance with AASB 116 *Property, Plant and Equipment*.

The associated borrowing has increased the Group's total interest-bearing liabilities and will result in ongoing finance costs in future reporting periods. The directors consider this acquisition to be a significant investing and financing transaction during the period as it materially impacted the Group's statement of financial position, cash flows and capital structure.

Reconciliation to Cash Flow:	\$'000
Total additions	10,299
Loan facility	<u>(6,650)</u>
Total property, plant and equipment excluding loan	<u>3,649</u>
Cash payment	<u>(3,648)</u>
Payment timing difference	<u><u>1</u></u>

Note 13. Right-of-use assets

	Consolidated	
	31 Dec	30 Jun
	2025	2025
	\$'000	\$'000
<i>Non-current assets</i>		
Land and buildings - right-of-use	3,430	3,430
Less: Accumulated depreciation	<u>(1,561)</u>	<u>(1,431)</u>
	<u><u>1,869</u></u>	<u><u>1,999</u></u>

The Group leases land and buildings for its offices and warehouses under an agreement for 5 years to 30 June 2028, with the option to extend the lease by 5 years to 30 June 2033.

Reconciliations

Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:

Consolidated	Land and buildings \$'000
Balance at 1 July 2025	1,999
Depreciation expense	<u>(130)</u>
Balance at 31 December 2025	<u><u>1,869</u></u>

Note 14. Borrowings

	Consolidated	
	31 Dec	30 Jun
	2025	2025
	\$'000	\$'000

Current liabilities

Bank loans - secured

	6,650	-
--	-------	---

During the half-year, the Group entered a new bank facility. The borrowing is measured at amortised cost in accordance with AASB 9.

On 14 October 2025, the Group entered into a Business Letter of Offer with National Australia Bank Limited (NAB) for a NAB Corporate Markets Loan facility with a total limit of \$6,650,000. The facility is intended to fund the purchase of non-residential industrial property.

The loan facility secured at approximately 70% loan-to-value, settled on 26 Nov 2025. The loan is interest-only, with the principal repayable in full on the final repayment date.

Interest is charged at a floating rate, being the Bank Bill Swap Reference Rate (BBSY) plus applicable margins, with interest repriced every three months. A facility fee of 1.40% per annum is payable on the approved facility limit.

Assets pledged as security

- A General Security Agreement over all present and future assets of the Group;
- a registered mortgage over the property located at 100–104 Adderley Street West, Auburn, NSW; and
- a Guarantee and Indemnity provided by the Group, supported by a general security agreement over all of its assets.

Financing arrangements

Unrestricted access was available at the reporting date to the following lines of credit:

	Consolidated	
	31 Dec	30 Jun
	2025	2025
	\$'000	\$'000

Total facilities

Bank loans

	6,650	-
--	-------	---

Used at the reporting date

Bank loans

	6,650	-
--	-------	---

Unused at the reporting date

Bank loans

	-	-
--	---	---

Note 15. Other liabilities

	Consolidated	
	31 Dec 2025 \$'000	30 Jun 2025 \$'000
<i>Current liabilities</i>		
Other liabilities	67	67
<i>Non-current liabilities</i>		
Other liabilities	227	227
	<u>294</u>	<u>294</u>

As at 31 December 2025, an amount of \$294,000 remains payable to the Australian Competition and Consumer Commission ('ACCC') under the deferred settlement arrangement that commenced in 2019. An amount of \$85,000 is payable per year, with the final payment due in 2029.

Note 16. Issued capital

	31 Dec 2025 Shares	30 Jun 2025 Shares	Consolidated 31 Dec 2025 \$'000	Consolidated 30 Jun 2025 \$'000
Ordinary shares - fully paid	48,809,563	48,809,563	3,538	3,538

Ordinary shares

Ordinary shares entitle the holder to participate in any dividends declared and any proceeds attributable to shareholders should the Company be wound up, in proportions that consider both the number of shares held and the extent to which those shares are paid up. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Note 17. Dividends

Dividends

Dividends paid during the financial half-year were as follows:

	31 Dec 2025 \$'000	Consolidated 31 Dec 2024 \$'000
Final unfranked dividend paid during the half-year for the year ended 31 December 2025 of nil cents (31 December 2024: 2.0 cents) per ordinary share.	-	976

Note 18. Fair value measurement

Fair value hierarchy

The following tables detail the Group's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

Note 19. Contingent liabilities

Bank guarantees of \$198,000 (30 June 2025: \$198,000) exist at year-end in respect of the Group's obligations under the premises lease arrangements.

Note 20. Commitments

The Group did not have any commitments as at 31 December 2025 (30 June 2025: none).

Note 21. Related party transactions

Parent entity

Cryosite Limited is the parent entity.

Subsidiary

The group has one subsidiary, Cryosite Property Pty Ltd.

Transactions with related parties

The following transactions occurred with related parties:

	Consolidated	Consolidated
	31 Dec	31 Dec
	2025	2024
	\$	\$
Other income:		
Interest received from subsidiaries	18,159	-
Payment for other expenses:		
Interest paid to subsidiaries	20,876	-
Other expenses paid to subsidiaries	37,455	-
Other transactions:		
Rental expenses paid to subsidiary	41,715	-

Receivable from and payable to related parties

The following balances are outstanding at the reporting date in relation to transactions with related parties:

	Consolidated	Consolidated
	31 Dec	30 Jun
	2025	2025
	\$	\$
Current receivables:		
Trade receivables from subsidiaries	3,487,591	-

Intercompany Receivables Settlement Terms:

During the period, Cryosite Limited advanced \$3.49 million to its wholly owned subsidiary, Cryosite Property Pty Ltd, to partially fund the acquisition of a warehouse property located at 100–104 Adderley Street West, Auburn, NSW.

The intercompany loan is unsecured and bears market interest at arm of length (the subsidiary applies the same interest rate as its Nab loan facility and accrues interest expense every month for both internal and external loans) and is repayable when surplus cash is available. The loan is subordinated to the subsidiary's external bank borrowings.

Recoverability:

Management has assessed the recoverability of the intercompany loan and determined that no impairment provision is required. The subsidiary holds a warehouse property with a carrying amount of \$10.1 million, among which most attributes to its land value. The property located close to major road networks of Sydney, where land value is appreciating over time, particularly in Sydney.

The directors do not consider there to be any credit risk associated with the loan, and therefore the expected credit loss is assessed as immaterial.

Terms and conditions

All transactions were made on normal commercial terms and conditions and at market rates.

Note 22. Events after the reporting period

No matter or circumstance has arisen since 31 December 2025 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

For personal use only

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 31 December 2025 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in black ink that reads "Mark Kerr".

Mark Kerr
Non-Executive Chairman

26 February 2026

For personal use only

Independent Auditor's Review Report to the Members of Cryosite Limited

Conclusion

We have reviewed the accompanying half-year financial report of Cryosite Limited and its controlled entity (the "Group"), which comprises the consolidated statement of financial position as at 31 December 2025, consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, significant accounting policies, explanatory notes and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Cryosite Limited and its controlled entity is not in accordance with *the Corporations Act 2001*, including:

- (i) giving a true and fair view of the Group's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with *ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity (ASRE 2410)*. Our responsibilities are further described in the Auditor's responsibilities for the review of the half-year financial report section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants* (including Independence Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Directors' responsibility for the half-year financial report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors' determine is necessary to enable the presentation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. *ASRE 2410* requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and of its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Forvis Mazars

Forvis Mazars Audit & Assurance Pty Ltd

A. Aupied

Alexis Aupied

Director

26 February 2026

For personal use only

Principal Services

1. Clinical Trials Logistics & Distribution
2. Biological Storage
3. Cell & Gene Therapies Depot Services

Specialising In:

- GMP Temperature-Controlled Storage
- Investigational Medicinal Product (IMP) Status Management
- Date Extension Labelling for IMP unregistered goods
- GMP Secondary Packaging
- Scheduled Drug Distribution (Schedule 8 drugs)
- Destruction Services including certificates
- Reverse Logistics>Returns Management from clinical sites and hospitals
- Import and Export Services
- Validated Transport Solutions
- Long-Term Storage Options
- Legacy Cord Blood and Tissue Storage

www.cryosite.com

TGA Licence Number MI-18072008-LI-002488-11